Background Vascular dementia (VaD) accounts for 15-20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng, Ginkgo biloba and Crocus sativus extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention.

中文翻译：

---

赛络通（SLT）治疗血管性痴呆和阿尔茨海默病伴脑血管病的 III 期随机对照试验研究方案

背景血管性痴呆 (VaD) 占所有痴呆病例的 15-20%。它是一种具有复杂病理生理基础的获得性认知障碍综合征。一种由人参、银杏叶和番红花提取物组成的新型草药制剂（赛络通；SLT）被开发用于治疗 VaD。临床前动物研究发现记忆力和致病性生化参数有显着改善。在急性和慢性毒性研究中显示了 SLT 的适当安全性，并且 SLT 的早期临床试验证明了 VaD 患者的认知能力增强。需要一项具有较长干预期的完全有力的研究来确认这种新型干预的有效性和安全性。